Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns | Zendy

Heloísa Resende | Zendy; Leandro Ladislau | Zendy; Ana Carolina Cardoso | Zendy; Juliana Dinéia Perez | Zendy; Biazi Ricieri Assis | Zendy; Paôla Cardoso | Zendy; Pedro Henrique Adário Marassi | Zendy; Vivienne Carduz Castilho | Zendy

Open Access

Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns

Author(s) -

Heloísa Resende,

Leandro Ladislau,

Ana Carolina Cardoso,

Juliana Dinéia Perez,

Biazi Ricieri Assis,

Paôla Cardoso,

Pedro Henrique Adário Marassi,

Vivienne Carduz Castilho

Publication year - 2021

Publication title -

jco global oncology

Language(s) - English

Resource type - Journals

ISSN - 2687-8941

DOI - 10.1200/go.20.00649

Subject(s) - biosimilar , trastuzumab , medicine , breast cancer , cancer , family medicine , oncology , intensive care medicine

Breast cancer is the most common malignancy in Brazilian women, with 66,280 new cases in 2020 (with 20% overexpressing human epidermal growth factor receptor 2 [HER2]). The trastuzumab biosimilar was the first oncology biosimilar approved in Brazil for HER2-positive breast cancer treatment. This study aimed to assess the current level of knowledge of biosimilars, comfort of use, extrapolation indications, and switching of practices among oncologists in Brazil.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research